Drug Profile
XL 281
Alternative Names: BMS-908662; XL-281Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Malignant melanoma
Most Recent Events
- 11 Jun 2013 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma in USA (NCT01245556)
- 31 Oct 2011 XL 281 is no longer licensed to Bristol-Myers Squibb
- 29 Sep 2011 Bristol-Myers Squibb completes a phase I/II trial in Colorectal cancer (metastatic disease, in combination with cetuximab) in US and Canada (NCT01086267)